©2024 Stanford Medicine
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
Not Recruiting
Trial ID: NCT04285580
Purpose
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a
single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular
Hypertension
Official Title
An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
Stanford Investigator(s)
Ann Caroline Fisher, MD
Clinical Associate Professor, Ophthalmology
Eligibility
Inclusion Criteria:
- Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment
- Participant is currently a nonsmoker and has not smoked any nicotine-containing
products within the previous 6 months
Exclusion Criteria:
- Current or anticipated enrollment in another investigational drug or device study
- Females who are pregnant, nursing, or planning a pregnancy during the study
Intervention(s):
drug: Bimatoprost SR
drug: LUMIGAN
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305